Budget Impact Analysis of the Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors – Nilotinib in the First and Second Lines of Therapy
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.1095
https://www.valueinhealthjournal.com/article/S1098-3015(15)03171-X/fulltext
Section Title :
Research Podium Presentations - Session 1 and Session 2
Section Order :
595
First Page :
A443
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03171-X&doi=10.1016/j.jval.2015.09.1095